CD19, a B-cell surface protein, is expressed across B-cell development and it is expressed on almost all B-cell malignancies, such as ALL, chronic lymphocytic leukemia (CLL) and several non ...

defects in B-cell receptors signaling and B cell development have been described, especially mutations in CD19(8), B-cell activating factor of the tumor necrosis factor family receptor (BAFF-R ...

safety and efficacy data from an investigator-sponsored trial evaluating the combination of Orca-T with allogeneic CD19/CD22-CAR-T cells in patients with high-risk B-cell acute lymphoblastic ...

Sana Biotechnology has become the latest cell therapy biotech to shift resources from cancer to autoimmune diseases as part of a ...

but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. For more information about Estrella, please visit www.estrellabio.com.

Interested parties can access the live webcasts for the conferences in the Investors section of CARGO’s website under News & Events. The webcast replays will be available after the conclusion of the ...

CARGO Therapeutics (CRGX) announced that its first abstract on CRG-023 will be presented as a poster at the upcoming 66th American Society of ...

Researchers previously reported that CAR-T may lead to complications known as immune effector cell-associated ... of either ...